Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1 - Report - MDSpire

Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1

  • By

  • Junseok Jeon

  • Youngmin Yoon

  • Kyungho Lee

  • Heasil Moon

  • Jung Eun Lee

  • Ghee Young Kwon

  • Wooseong Huh

  • Hye Ryoun Jang

  • June 24, 2026

  • 0 min

Share

Prognostic Biomarkers for Favorable Outcomes in IgA Nephropathy Patients

Overview

This study identifies serum TGF-β1 and MCP-1 as potential biomarkers for predicting favorable outcomes in IgA nephropathy (IgAN) patients undergoing immunosuppressive therapy.

Background

IgA nephropathy is the most prevalent form of primary glomerulonephritis, with a highly variable clinical course that can lead to end-stage kidney disease in a significant proportion of patients. Identifying reliable prognostic markers is essential for optimizing treatment strategies and improving patient outcomes, particularly in the context of immunosuppressive therapy.

Data Highlights

ParameterGood Prognosis
Patients with good prognosis120 (59.4%)
10-year follow-up risk of ESKDSignificantly lower
Higher serum TGF-β1 (aOR)1.16 (95% CI, 1.04–1.31)
Lower serum MCP-1 (aOR)0.99 (95% CI, 0.97–1.00)
Less intrarenal CD20+ cell infiltration (aOR)0.22 (95% CI, 0.07–0.73)

Key Findings

  • 59.4% of patients exhibited a good prognosis after immunosuppressive therapy.
  • Higher serum TGF-β1 levels were associated with a favorable prognosis.
  • Lower serum MCP-1 levels independently predicted good prognosis in treated patients.
  • Less intrarenal CD20+ cell infiltration indicated a better prognosis in patients receiving supportive care only.
  • Multivariable analyses identified several independent predictors of good prognosis, including immunosuppressive therapy and lower urine protein-to-creatinine ratio.

Clinical Implications

The identification of serum TGF-β1 and MCP-1 as prognostic biomarkers may assist clinicians in making informed treatment decisions for IgAN patients.

Conclusion

Serum TGF-β1 and MCP-1 levels may serve as prognostic indicators in IgAN.

Related Resources & Content

  1. KDIGO, KDIGO, 2021 -- Guideline for the Management of Glomerular Diseases
  2. Blood TGF-β1 and miRNA-21-5p levels predict renal fibrosis and outcome in IgA nephropathy, PMC, 2023 -- Blood TGF-β1 and miRNA-21-5p levels predict renal fibrosis and outcome in IgA nephropathy
  3. mRNA Expression Levels of the Transforming Growth Factor β1 Gene as a Potential Prognostic Indicator in Pediatric Inflammatory Bowel Diseases, Unlike Its Protein Product
  4. Bone Marrow Transplantation — Monocytosis as a Predictor of Chronic Graft-versus-Host Disease Outcomes
  5. Journal of Gastroenterology — Serum IL-6 Levels as Predictive Biomarkers for the Effectiveness of Atezolizumab Combined with Bevacizumab in Hepatocellular Carcinoma Patients
  6. Clinical Rheumatology — Expression levels of CXCL10 and STAT1 in lupus nephritis and the therapeutic impact of triptolide
  7. KDIGO 2021 Guideline for the Management of Glomerular Diseases – KDIGO
  8. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy - ScienceDirect
  9. Blood TGF-β1 and miRNA-21-5p levels predict renal fibrosis and outcome in IgA nephropathy - PMC

Original Source(s)

Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1

  • by Junseok Jeon, Youngmin Yoon, Kyungho Lee, Heasil Moon, Jung Eun Lee, Ghee Young Kwon, Wooseong Huh, Hye Ryoun Jang

  • June 24, 2026

Related Content

A case report: Retroperitoneal dedifferentiated liposarcoma with heterologous myogenic differentiation and testicular metastasis

Untargeted or Non-Targeted Screening?

Is there a meaningful distinction? A panel of experts debate.

  • June 19, 2026

  • 6 min
First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.